All IndicationsOncologyPhase 3Phase 3Phase 2Phase 2Phase 2Phase 2
🎗️
Multiple Myeloma
5
Companies
6
Drug Programs
2
Phase 3
0
Upcoming PDUFAs
Competitors
JNJ
Johnson & Johnson
Bortezomib
JNJ
Johnson & Johnson
Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)
REGN
Regeneron Pharmaceuticals, Inc.
REGN5458
BreakthroughFast TrackOrphan Drug
BMY
Bristol-Myers Squibb Company
Arlocabtagene Autoleucel
INCY
Incyte Corporation
Ruxolitinib 25 mg
GERN
Geron Corporation
Imetelstat (7.5 mg/kg)
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Bortezomib | Phase 3 | — | — | — |
| JNJ Johnson & Johnson | Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD) | Phase 3 | — | — | — |
| REGN Regeneron Pharmaceuticals, Inc. | REGN5458 | Phase 2 | BTFTOD | — | — |
| BMY Bristol-Myers Squibb Company | Arlocabtagene Autoleucel | Phase 2 | — | — | — |
| INCY Incyte Corporation | Ruxolitinib 25 mg | Phase 2 | — | — | — |
| GERN Geron Corporation | Imetelstat (7.5 mg/kg) | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
2
Phase 2
4
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.